A Food and Drug Administration panel led by Commissioner Martin Makary recommended removing black box warnings from menopausal hormone therapy (MHT) labeling. The panel emphasized MHT benefits for severe vasomotor symptoms and criticized reliance on early 2000s Women's Health Initiative studies that had previously linked MHT to cancer and cardiovascular risks. Panelists and advocates noted updated evidence suggesting favorable benefit-risk profiles and urged broader patient access without restrictive warnings. The debate underscores evolving perspectives on MHT safety and calls for regulatory revision to support treatment availability.